Literature DB >> 3536254

Clinical pharmacokinetics of allopurinol.

G A Murrell, W G Rapeport.   

Abstract

Allopurinol is a widely used drug in the management of hyperuricaemia. It is rapidly and extensively absorbed following oral administration. The major and active metabolite, oxypurinol, is detected in the circulation within 15 minutes of allopurinol administration. Oxypurinol concentrations are higher than those of the parent drug and accumulation occurs during long term administration. Up to 80% of allopurinol is recovered in the urine within 24 hours, mainly in the form of oxypurinol. Allopurinol is negligibly absorbed after rectal administration. In animals, allopurinol is found in highest concentrations in vascular tissue, blood, liver, intestine and heart. It is negligibly bound to plasma proteins. Oxypurinol is eliminated by the kidney and has a much longer elimination half-life than allopurinol. Oxypurinol accumulates in patients with renal dysfunction; hence allopurinol dosages should be adjusted in such patients. Allopurinol inhibits the metabolism of 6-mercaptopurine and azathioprine, which require dosage modifications. The interaction of allopurinol with oral anticoagulants and phenytoin has not been clearly established in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536254     DOI: 10.2165/00003088-198611050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  35 in total

1.  [High pressure liquid chromatographic determination of allopurinol and oxipurinol in serum].

Authors:  R Endele; G Lettenbauer
Journal:  J Chromatogr       Date:  1975-12-10

2.  Variations in allopurinol metabolism by xanthinuric subjects.

Authors:  H A Simmonds; B Levin; J S Cameron
Journal:  Clin Sci Mol Med       Date:  1974-08

3.  Quantitation of oxypurines and allopurinol metabolites in biological fluids by cation-exchange chromatography.

Authors:  L Sweetman; W L Nyhan
Journal:  Anal Biochem       Date:  1969-10-01       Impact factor: 3.365

4.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

5.  Allopurinol: alteration in pyrimidine metabolism in man.

Authors:  W N Kelley; T D Beardmore
Journal:  Science       Date:  1970-07-24       Impact factor: 47.728

6.  The effect of dietary protein on the clearance of allopurinol and oxypurinol.

Authors:  W G Berlinger; G D Park; R Spector
Journal:  N Engl J Med       Date:  1985-09-26       Impact factor: 91.245

7.  Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome.

Authors:  K Yokochi; A Yokochi; K Chiba; T Ishizaki
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

8.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].

Authors:  I Walter-Sack; W Gröbner; N Zöllner
Journal:  Arzneimittelforschung       Date:  1979

10.  Formation of nucleotides of (6-14C)allopurinol and (6-14C)oxipurinol in rat tissues and effects on uridine nucleotide pools.

Authors:  D J Nelson; C J Buggé; H C Krasny; G B Elion
Journal:  Biochem Pharmacol       Date:  1973-08-15       Impact factor: 5.858

View more
  20 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.

Authors:  G M Peterson; R R Boyle; H W Francis; N W Oliver; J Paterson; R J von Witt; G R Taylor
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Managing Gout in the Patient with Renal Impairment.

Authors:  Eliseo Pascual; Francisca Sivera; Mariano Andrés
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

5.  Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?

Authors:  I Walter-Sack; J X de Vries; C Kreiner; A Ittensohn; G Stenzhorn; A Voss; E Weber
Journal:  Clin Investig       Date:  1993-03

6.  Allopurinol and oxypurinol in human breast milk.

Authors:  I Kamilli; U Gresser
Journal:  Clin Investig       Date:  1993-02

Review 7.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

8.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.

Authors:  L Lennard; B E Gibson; T Nicole; J S Lilleyman
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

Review 9.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

Review 10.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.